STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies

PRINCETON, N.J. and PARIS - September 26, 2012 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its Self-Apposing® stent.

Stents are implanted in the coronary arteries via a keyhole in the groin or in the wrist under angiography (X-ray imaging). Cardiologists use a delivery catheter to navigate through the arteries, reach the occluded vessel and deploy the stent. The new catheter to implant the STENTYS Self-Apposing stent adds a hydrophilic (slippery) coating and an ergonomic handle that considerably facilitates stent implantation in tortuous vessels.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, commented: “Feedback from cardiologists suggests the new delivery catheter is very user-friendly and we are confident this product enhancement will allow a greater range of patients to benefit from our STENTYS Self-Apposing stent technology.”

In its latest guidelines on AMI treatment, the European Society of Cardiology (ESC) calls attention to the importance of selecting the appropriate stent size, as the vessel in this setting is contracted and contains thrombus (clot), and to the complications that may result from inappropriate stent sizing. The STENTYS Self-Apposing® Stent solves that “stent-sizing dilemma”: it fits into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post-AMI phase.

About STENTYS:
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one-month mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

STENTYS
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

Europe: NewCap.
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

US: MacDougall Biomedical Communications
Kari Watson, Tel.: +1 781 235 3060
Christine Labaree, Tel.: +1 650 339 7533
stentys@macbiocom.com

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT